Tag: heart
Hey, Pfizer watchers, don’t forget Vyndaqel. The heart disease drug’s zooming...
All public attention for Pfizer these days is centered on its BioNTech-partnered COVID-19 vaccine. But while key phase 3 efficacy data for the experimental...
Teva back on the hook for $235M to GSK for heart...
After a jury in 2017 ordered Teva to pay $235 million for patent infringement of a GlaxoSmithKline heart drug, the generics giant convinced a district...
ESC: Merck’s Steglatro shows limited promise with heart failure hospitalization data
Late to the party against its SGLT2 diabetes rivals, Merck & Co.'s Steglatro has also tracked way behind in the class' growing presence in...
ESC: Novartis’ Entresto racks up a heart failure study win—but it’s...
As the bestselling drug in the heart failure space, Novartis' Entresto suffered a stinging setback last year in a novel indication—but there were some...
AstraZeneca scores speedy FDA review for Farxiga based on ‘innovative’ heart...
AstraZeneca has already taken impressive Farxiga heart failure outcomes results and parlayed them into a watershed approval. Looking at Farxiga's future in a competitive...
Lilly, Boehringer hit heart safety mark with Januvia rival Tradjenta. Is...
Boehringer Ingelheim and Eli Lilly’s Tradjenta is working to pick up share in an ultracompetitive diabetes market, and it’s hoping some new outcomes data...
